Initial Evaluation of Anti-1-amino-F-18 Flurocyclobutane-1carboxylic Acid (Anti-18F-FACBC) in the Assessment of Head and Neck Cancer: A Pilot Study.

Trial Profile

Initial Evaluation of Anti-1-amino-F-18 Flurocyclobutane-1carboxylic Acid (Anti-18F-FACBC) in the Assessment of Head and Neck Cancer: A Pilot Study.

Withdrawn prior to enrolment
Phase of Trial: Phase 0

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Head and neck cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 01 Feb 2018 Planned End Date changed from 31 Mar 2018 to 1 Feb 2018.
    • 01 Feb 2018 Planned primary completion date changed from 31 Mar 2018 to 1 Feb 2018.
    • 01 Feb 2018 Status changed from suspended to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top